-
Genrix Bio Pharmaceutical Partners with China Resource Medicine for Expanded Market Coverage
•
Chongqing Genrix Bio Pharmaceutical Co., Ltd (SHA: 688443), a Chinese biopharmaceutical company, has entered into a strategic partnership with China Resource Medicine Commercial Holdings Ltd. The collaboration aims to enhance channel management and strengthen presence in the healthcare and retail markets. Financial details of the agreement were not disclosed. By…
-
Takeda and Astellas Join Forces with Sumitomo Mitsui to Launch Drug Discovery Joint Venture
•
Japanese pharmaceutical giants Takeda (NYSE: TAK) and Astellas (TSE: 4503) have joined hands with compatriot bank Sumitomo Mitsui to establish a joint venture (JV) aimed at nurturing drug discovery start-ups. The yet-to-be-named JV will leverage the pharmaceutical companies’ expertise to foster innovation in the early stages of drug development.- Flcube.com
-
GenScript Biotech Corporation Reports 34.2% YOY Revenue Growth in 2023 Financial Results
•
China-based GenScript Biotech Corporation (HKG: 1548) has announced its financial results for 2023, reporting revenues of USD 839.5 million for the year, marking a 34.2% year-on-year (YOY) increase. External revenues from non-cell therapy business reached USD 554.5 million, up 8.9% YOY, while cell therapy sales soared to USD 285 million,…
-
Bristol Myers Squibb Enhances CAR-T Manufacturing with Cellares Platform, Securing Exclusive Access
•
Pharmaceutical giant Bristol Myers Squibb (BMS; NYSE: BMY) has secured a deal with Cellares, a U.S.-based cell therapy production platform, to bolster its manufacturing capacity for CAR-T therapies. In return for granting exclusive access to several of its fully automated systems, Cellares is set to receive up to USD 380…
-
Zai Lab Ltd Appoints New Greater China CCO as Liang Yi Exits
•
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced the appointment of Zhu Tong as the new Greater China Chief Commercial Officer (CCO), succeeding Liang Yi, who is departing from his role as both CCO and President of Greater China. Liang’s departure will become official on April 30. Zhu Tong’s…
-
China’s NMPA Introduces 12 Measures to Strengthen Drug Operation Administration
•
The National Medical Products Administration (NMPA) has issued a notification with 12 measures aimed at enhancing the administration and management of drug operations, effective immediately.
-
MSD Strikes Deal with GV20 Therapeutics to Test Anti-PD-1 Combo in Solid Tumor Therapies
•
Merck, Sharp & Dohme (MSD; NYSE: MRK), a global healthcare leader, has entered into a strategic collaboration with GV20 Therapeutics, a biopharmaceutical company specializing in antibody therapeutics with operations in both China and the U.S. The partnership aims to combine GV20’s groundbreaking IGSF8-targeted biologic, GV20-0251, with MSD’s best-selling anti-PD-1 therapy,…
-
Jiangsu Hengrui’s SHR-A2102 Earns FDA Fast Track Status for Urothelial Carcinoma Treatment
•
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a prominent pharmaceutical company in China, has announced that it has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for its pipeline candidate, SHR-A2102. This designation is in recognition of the drug’s potential to treat advanced urothelial carcinoma,…
